Is NCT07305818 recruiting in Rochester, MN?

Yes, NCT07305818 is currently recruiting participants at its Rochester, MN location. This graves disease clinical trial is actively enrolling qualified participants.

How do I join the graves disease clinical trial in Rochester?

To join this clinical trial in Rochester, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Rochester clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Graves Disease Clinical Trial in Rochester, MN

About This Graves Disease Study in Rochester

The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Sponsor: Merida Biosciences

Who Can Participate

Inclusion Criteria

Adults 18 to 65 years of age, inclusive, at the time of signing the ICF

Documented GD diagnosis,

Receiving stable dose of ATD (Antithyroid drug)

Body weight at least 50 kg (110 lb) and body mass index (BMI) 18.0-35.0 kg/m2, inclusive

Women of childbearing potential must agree to use highly effective contraceptive methods

Men with partners of childbearing potential or who are pregnant must agree to use a condom or strict abstinence

Signed informed consent to participate in the study

Willingness and ability, in the opinion of the investigator, to comply with protocol requirements and restrictions (eg, dosing, schedule of assessments).

Exclusion Criteria

History of:

total thyroidectomy.

History of hyperthyroidism not caused by GD (eg, toxic adenoma, toxic multinodular goiter).

History of thyroid storm.

History of agranulocytosis, anemia, leukopenia, thrombocytopenia, vasculitis, or liver toxicity due to prior ATD therapy Treatment with RAI therapy within 12 months prior to Screening

Likely to require definitive treatment for GD (RAI therapy or thyroidectomy) during the study, based on GD history and anticipated prognosis.

Use of levothyroxine, desiccated thyroid extract, or T3 at any dose within 6 weeks prior to Screening.

Current active or chronic moderate-to-severe TED per EUropean Group On Graves' Orbitopathy (EUGOGO) criteria as judged by the investigator at Screening

History of TED-directed medical treatment (including IV/oral steroids, immunosuppressants, or teprotumumab), surgical treatment, and/or orbital radiation within 3 months prior to Screening, or per required prohibited concomitant therapy washout criteria in the protocol (whichever is longer)

Major surgery or use of iodinated contrast within 3 months prior to planned IMP dosing.

Active systemic autoimmune disease requiring treatment that causes undue risk in the opinion of the investigator.

History of cardiovascular, respiratory, renal, gastrointestinal, endocrinological (other than GD), hematological, immunodeficiency, or neurological disorders that may constitute a risk when taking the IMP or interfere with data interpretation.

History of liver disease

Pregnant, breastfeeding, or planning to become pregnant during the study

Treatment with prohibited medications prior to planned IMP dosing or likely to require prohibited concomitant therapy during the study

Live vaccine(s) or mRNA vaccine(s) within 1 month prior to IMP dosing, or plans to receive such vaccines during the study

Treatment with any investigational drug within within 3 months or 5 half-lives (whichever is longer) prior to enrollment

Total IgG level \<700 mg/dL at Screening

Any of the following at Screening (confirmed by single repeat measurement, if deemed necessary):

ALT or AST \>1.5 × ULN

Total bilirubin \>1.5 × ULN

Estimated glomerular filtration rate (eGFR) \<75 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation

Positive result for HIV antibody, HBsAg, or hepatitis C antibody with detectable viral RNA levels at Screening

Positive drug screen or positive test for alcohol

12-lead ECG demonstrating any of the following at Screening:

QTcF interval \>450 ms

QRS interval \>120 ms

PR interval \>220 ms

Blood pressure measurements demonstrating any of the following at Screening:

Systolic blood pressure ≥140 mmHg

Diastolic blood pressure ≥90 mmHg

Heart rate \<45 bpm or \>100 bpm

Donated more than 500 mL of blood in the 2 months prior to signing the ICF

Current enrollment or past participation within 3 months or 5 half-lives (whichever is longer) prior to signing the ICF in any other clinical trial involving an IMP

Refusal to adhere to lifestyle considerations as defined in the protocol

Employee of the investigator, clinic, or sponsor with direct involvement in the proposed study or other studies under the direction of the investigator or clinic, as well as family members of the employee or investigator

Any other conditions that, in the opinion of the investigator or the sponsor, could interfere with participation in or completion of the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT07305818) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Graves Disease Treatment Options in Rochester, MN

If you're searching for graves disease treatment options in Rochester, MN, this clinical trial (NCT07305818) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced graves disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all graves disease clinical trials near you to find additional studies recruiting in your area.

Graves Disease Clinical Trial in Rochester, MN

Expert Care in Rochester

IRB Approved

No-Cost Care

Apply for This Rochester Location

Why Participate?

Simple Process